Interestingly, exogenous administration of anti-IL-1α antibodies, but not IL-1Ra, has been shown to ameliorate intestinal inflammation and increase repair and recovery of the epithelial barrier following DSS-induced colitis (68). This evidence concerns the gene IL1A and colitis.